Preview

Вопросы современной педиатрии

Расширенный поиск

СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПАПИЛЛОМАВИРУСНОЙ ИНФЕКЦИИ И ВОЗМОЖНОСТИ ЕЕ ПРОФИЛАКТИКИ

Аннотация

В статье анализируются вопросы применения квадривалентной вакцины Гардасил против 6, 11, 16 и 18-го типов вируса папилломы человека (ВПЧ), ответственных за возникновение 70% случаев рака шейки маки и 90% аногенитальных кондилом. Результаты широкомасштабных исследований свидетельствуют о почти 100% эффективности вакцины в предотвращении предраковых интраэпителиальных дисплазий шейки матки, вульвы и влагалища, аногенитальных кондилом, обусловленных вакцинными типами ВПЧ, а также о ее высокой иммуногенности и практически полной безопасности. Вакцина включена в Национальные календари прививок многих стран. Полученные данные позволяют надеяться, что вакцинация против рака шейки матки в самом ближайшем будущем будет включена в российский Национальный календарь прививок.
Ключевые слова: вирус папилломы человека, рак шейки матки, квадривалентная вакцина против вируса папилломы человека, эффективность, иммуногенность, безопасность
(Вопросы современной педиатрии. 2009; 8(3):35-41)

Об авторах

И.С. Тарасова
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии, Москва
Россия


В.М. Чернов
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии, Москва
Россия


А.Г. Румянцев
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии, Москва
Россия


Список литературы

1. Румянцев А.Г. Профилактика и контроль инфекционных заболеваний в первичном звене здравоохранения. Руководство для врачей. Часть 1. М.: Медпрактика–М. 2007. С. 528.

2. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancerbase no. 5, version 2.0. Lyon, France: IARC Press. 2004. Доступно на: http://www-dep.iarc.fr/globocan/methods.htm.

3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. Cancer J. Clin. 2007; 57 (1): 43–66.

4. World Health Organization. Initiative for Vaccine Research. Viral cancers. URL: http://www.who.int/vaccine_research/diseases/viral_cancers/en/print.html.

5. Insinga R.P., Glass A.G., Rush B.B. The health care costs of cervical human papillomavirus related disease. Am. J. Obstet. Gynecol. 2004; 191 (1): 114–120.

6. Goldie S.J., Kuhn L., Denny L. et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost effectiveness. JAMA. 2001; 285 (24): 3107–3115.

7. Clifford G.M., Rana R.K., Franceschi S., et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 2005; 14 (5): 1157–1164.

8. Muñoz N., Bosch F.X., de Sanjosé S. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003; 348 (6): 518–527.

9. Clifford G.M., Smith J.S., Plummer M., et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer. 2003; 88 (11): 63–73.

10. Schiffman M., Castle P.E. Human papillomavirus: epidemiology and public health. Arch. Pathol. Lab. Med. 2003; 127 (8): 930–934.

11. Wiley D.J., Douglas J., Beutner K. et al. External genital warts: diagnosis, treatment, and prevention. Clin. Infect. Dis. 2002; 35 (Suppl. 2): 210–224.

12. Daling J.R., Madeleine M.M., Schwartz S.M. et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol. Oncol. 2002; 84 (2): 263–270.

13. Madeleine M.M., Daling J.R., Carter J.J. et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J. Natl. Cancer Inst. 1997; 89 (20): 1516–1523.

14. Frisch M. On the etiology of anal squamous carcinoma. Dan. Med. Bull. 2002; 49 (3): 194–209.

15. Partridge J.M., Koutsky L.A. Genital human papillomavirus infection in men. Lancet Infect. Dis. 2006; 6 (1): 21–31.

16. Gillison M.L., Lowy D.R. A causal role for human papillomavirus in head and neck cancer. Lancet. 2004; 363 (9420): 1488–1489.

17. Green G.E., Bauman N.M., Smith R.J.H. Pathogenesis and treatment of juvenile onset recurrent respiratory papillomatosis. Otolaryngol. Clin. North. Am. 2000; 33 (1) 187–207.

18. Winer R.L., Lee S.K., Hughes J.P. et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 2003; 157 (3): 218–226.

19. Kjaer S.K., Chackerian B., van den Brule A.J. et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow up study of virgins starting sexual activity (intercourse). Cancer Epidemiol. Biomarkers Prev. 2001; 10 (2): 101–106.

20. Marrazzo J.M., Stine K., Koutsky L.A. Genital human papillomavirus infection in women who have sex with women: a review. Am. J. Obstet. Gynecol. 2000; 183 (3): 770–774.

21. Ho G.Y., Bierman R., Beardsley L. et al. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998; 338 (7): 423–428.

22. Molano M., Van den Brule A., Plummer M. et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population based, 5 year follow up study. Am. J. Epidemiol. 2003; 158 (5): 486–494.

23. Ho G.Y., Burk R.D., Klein S. et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 1995; 87 (18): 1365–1371.

24. Schlecht N.F., Platt R.W., Duarte-Franco E. et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 2003; 95 (17): 1336–1343.

25. Schiffman M., Kjaer S.K. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. 2003; 31: 14–19.

26. Koshiol J., Lindsay L., Pimenta J.M., et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am. J. Epidemiol. 2008; 168 (2): 123–137.

27. Castellsagué X., Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives, and tobacco smoking. J. Natl. Cancer Inst. Monogr. 2003; 31: 20–28.

28. Appleby P., Beral V., Berrington de González A. et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007; 370 (9599): 1609–1621.

29. Appleby P., Beral V., Berrington de González A. et al. Carcinoma in the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma in the cervix and 23,017 women without carcinoma in the cervix from 23 epidemiological studies. Int. J. Cancer. 2006; 118 (6): 1481–1495.

30. Palefsky J.M., Holly E.A. Chapter 6: Immunosupression and co-infection with HIV. J. Natl. Cancer Inst. Monogr. 2003; 31: 41–46.

31. Smith J.S., Herrero R., Bosetti C. et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 2002; 94 (21): 1604–1613.

32. Smith J.S., Bosetti C., Muñoz N., et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case control study. Int. J. Cancer. 2004; 111 (3): 431–439.

33. Castle P.E., Giuliano A.R. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients – assessing their roles as human papillomavirus cofactors. J. Natl. Cancer Inst. Monogr. 2003; 31: 29–34.

34. Wright T.C. Current status of HPV vaccination recommendations. HPV today. 2008; 14: 8–9.

35. Hofmann K.J., Cook J.C., Joyce J.G. et al. Sequence determination of human papillomavirus type 6a and assembly of virus like particles in Saccharomyces cerevisiae. Virology. 1995; 209 (2): 506–518.

36. Koutsky L.A., Ault K.A., Wheeler C.M. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 2002; 347 (21): 1645–1651.

37. Mao C., Koutsky L.A., Ault K.A., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 2006; 107 (1): 18–27.

38. Villa L.L., Costa R.L., Petta C.A. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6 (5): 271–278.

39. Villa L.L., Costa R.L., Petta C.A. et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br. J. Cancer. 2006; 95 (11): 1459–1466.

40. Garland S.M., Hernandez–Avila M., Wheeler C.M. et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007; 356 (19): 1928–1943.

41. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007; 356 (19): 1915–1927.

42. Pagliusi S.R., Aguado T.M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004; 23 (5): 569–578.

43. ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 2003; 188 (6): 1383–1392.

44. ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 2003; 188 (6): 1393–1400.

45. Ault K.A., Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369 (9576): 1861–1868.

46. Schiller J.T., Castellsagué X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus like particles vaccine clinical trial results. Vaccine. 2008; 26 (Suppl. 10): 53–56.

47. Markowitz L.E., Dunne E.F., Saraiya M. et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2007; 56 (RR–2): 1–24.

48. Joura E.A., Leodolter S., Hernandez-Avila M. et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 69 (9574): 693–702.

49. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J. Infect. Disease. 2007; 196 (10): 1438–1446.

50. Muñoz N., Manalastas R. Jr, Pitisuttithum P. et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double blind trial. Lancet. 2009; 373 (9679): 1949–1957.

51. Villa L.L., Ault K.A., Giuliano A.R. et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006; 24 (7–28): 5571–5583.

52. Poland G.A., Jacobson R.M., Koutsky L.A. et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2 year randomized controlled clinical trial. Mayo Clin. Proc. 2005; 80 (5): 601–610.

53. Block S.L., Nolan T., Sattler C. et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118 (5): 2135–2145.

54. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis J. 2007; 26 (3): 201–209.

55. Olsson S.E., Villa L.L., Costa R.L. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus like particle (VLP) vaccine. Vaccine. 2007; 25 (26): 4931–4939.

56. Rowhani–Rahbar A., Mao C., Hughes J. et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. Abstract book of the 25th International Papillomavirus Conference. May 8–14, 2009, Malmo, Sweden.

57. Koutsky L.A., Harper D.M. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine. 2006; 24 (Suppl. 3): 114–121.

58. American College of Obstetricians-Gynecologists ACOG Committee Opinion. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Number 330, April 2006. Obstet Gynecol. 2006; 107 (4): 963–968.

59. Committee on Adolescent Health Care; ACOG Working Group on Immunization. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet. Gynecol. 2006; 108 (3): 699–705.

60. World Health Organization. New vaccines against cervical cancer major opportunity for developing world [news release]. December 12, 2006. Доступно на: http://www.who.int/mediacentre/news/releases/2006/pr73/en/print.html.


Для цитирования:


Тарасова И., Чернов В., Румянцев А. СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПАПИЛЛОМАВИРУСНОЙ ИНФЕКЦИИ И ВОЗМОЖНОСТИ ЕЕ ПРОФИЛАКТИКИ. Вопросы современной педиатрии. 2009;8(3):35-41.

For citation:


Tarasov I., Chernov V., Rumyantsev A. MODERN DATA ON PAPILLOMA VIRUS INFECTION, AND OPPORTUNITIES OF ITS PROPHYLAXIS. Current Pediatrics. 2009;8(3):35-41. (In Russ.)

Просмотров: 273


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)